Why Are Shares of Valeant Pharmaceuticals International Inc Plunging?

Should you be buying shares of Valeant Pharmaceuticals International Inc (TSX:VRX)(NYSE:VRX)?

| More on:
The Motley Fool

On Thursday morning, Valeant Pharmaceuticals International Inc (TSX: VRX)(NYSE: VRX) reported earnings for the second quarter of 2014. Revenue came in at $2.4 billion (all figures in U.S. dollars) and cash earnings per share was $1.91, both of which were in line with consensus. But as of this writing, the stock is down $10 for the day, and is now trading below $130 (earlier in 2014 the shares were trading as high as $170).

So why has the stock plunged so much? And has this provided an opportunity?

The positives

Valeant’s results once again demonstrated its ability to grow sales from its acquired businesses, all while running them at a lower cost structure. In the second quarter, “same-store organic growth ex-generics” grew 10% year-over-year.

Included in this number is 12% growth at Bausch & Lomb, which Valeant bought for $8.7 billion about a year ago. This holds significance because of Valeant’s bid for Botox maker Allergan Inc (NYSE: AGN) – in fact Valeant CEO Michael Pearson said during the conference call that Bausch & Lomb “will serve as a model for what we hope to achieve for Allergan.”

Lowering guidance

Analysts were expecting Valeant’s guidance to be lowered after the company sold its injectables business for $1.4 billion. But the revenue impact of $230 million was a little over 50% higher than what these analysts were expecting.

As a result, the company’s FY2014 guidance calls for revenue of $8.0-$8.3 billion, compared to the previous forecast of $8.3-$8.7 billion. This doesn’t seem to be a particularly big drop; did the market overreact? And if so, are Valeant’s shares now a bargain?

Not so fast

Make no mistake: Valeant’s shares are still very expensive. To illustrate, last year the company made $5.8 billion in revenue. But the market value of the company (after factoring in net debt) is over $50 billion. Clearly there are still plenty of believers. Or to put it more cynically, there are plenty of momentum investors willing to bet on continued growth. If Valeant falters, those investors could easily sell the stock en masse, which would be devastating for the share price.

Making matters worse, it is very difficult to discern just how profitable the company is. According to generally accepted accounting standards, Valeant isn’t even profitable at all, losing $2.70 per share in 2013.

This should be worrying enough. But there are also a lot of very smart people betting against Valeant, including Jim Chanos, who became famous for betting against Enron before its collapse. If Mr. Chanos is right again, you don’t want to be caught on the other side of that bet.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

young woman celebrating a victory while working with mobile phone in the office
Dividend Stocks

3 CRA Benefits Most Canadians Can Grab in 2024

You can save on taxes by claiming the dividend tax credit on Fortis Inc (TSX:FTS) shares.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »